List view / Grid view
26 February 2016 | By Rodrigo Barnes, Chief Technology Officer at Aridhia
Here, Rodrigo Barnes, Chief Technology Officer at Aridhia, discusses how data analytics can add value to proof of concept trials...
23 February 2016 | By Victoria White
Given the key role of epigenetics in all tumour types, Desktop Genetics' research has wide potential applications across all histological types of cancer...
19 February 2016 | By DiscoverX Corporation
Diversity PLUS Panel contains 12 human primary cell systems from multiple tissues that model human disease for predictive insight into drug efficacy and MOA...
12 February 2016 | By DiscoverX Corporation
If you are looking to advance compounds to the clinic, BioMAP® phenotypic profiling services will predict the behaviour of your drug candidates in patients...
8 February 2016 | By Victoria White
Biogen’s new membership follows the launch of the new CTTV Target Validation Platform, which helps researchers identify therapeutic targets for new medicines...
23 September 2015 | By Victoria White
Inquiro gathers all unstructured data – from R&D to preclinical data – and allows researchers to organise and interconnect such data, facilitating large-scale collaborations among geographically distant research teams...
11 September 2015 | By Victoria White
Researchers have developed a new method for studying the targets and effects of cancer drugs using data from discovery mass spectrometry experiments...
7 July 2015 | By Oxford Global
The 2nd Annual Drug Discovery USA Congress is taking place on the 29th & 30th of October 2015 in Boston, USA...
4 March 2015 | By Retrogenix
New technology aims to reduce animal testing and improve safety testing of chemicals...
19 May 2014 | By PerkinElmer
The Opera Phenix™ delivers uncompromising speed and sensitivity, accelerating the understanding of disease and discovery of new and more effective treatment therapies...
27 March 2014 | By GlaxoSmithKline
Novel scientific collaboration to use genomics and big data to drive drug discovery...
